Related Experiment Video

Updated: Aug 9, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

Maria Debiec-Rychter1, Raf Sciot, Axel Le Cesne

  • 1Department of Human Genetics, University of Leuven and University Hospital Gasthuisberg, O&N Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium.

European Journal of Cancer (Oxford, England : 1990)
|April 21, 2006
PubMed

Insights

Tumour mutations significantly impact treatment response in advanced gastrointestinal stromal tumours (GISTs). KIT exon 9 mutations are linked to poorer outcomes, suggesting tailored imatinib dosing for better survival.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Advanced gastrointestinal stromal tumours (GISTs) are often treated with imatinib.
  • Previous studies indicated imatinib dose dependency for progression-free survival in GISTs.

Purpose of the Study:

  • To investigate the correlation between tumour mutational status and clinical response to imatinib in advanced GISTs.
  • To identify specific mutations that predict patient outcomes with imatinib therapy.

Main Methods:

  • Analysis of pre-treatment GIST samples from 377 patients in a randomized EORTC phase III trial.
  • Detection of KIT or PDGFRA mutations using D-HPLC and direct sequencing of tumour DNA.
  • Correlation of mutation types with progression-free survival and overall survival data.

Main Results:

  • KIT exon 9-activating mutations were the strongest adverse prognostic factor, significantly increasing progression (171%) and death (190%) risk compared to KIT exon 11 mutants.
  • Patients lacking detectable KIT or PDGFRA mutations also showed increased progression (108%) and death (76%) risk.
  • High-dose imatinib (800 mg daily) significantly improved progression-free survival (61% risk reduction) in patients with KIT exon 9 mutations.

Conclusions:

  • Tumour genotype is a critical prognostic factor for progression-free and overall survival in advanced GIST patients treated with imatinib.
  • Specific mutations, particularly KIT exon 9, necessitate differential treatment strategies.
  • KIT exon 9 mutant GIST patients benefit most from high-dose (800 mg daily) imatinib therapy.

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...